Cytomel (Liothyronine) FDA Approval History

Original Approval and Early Regulatory History

Cytomel received its initial FDA approval in 1956 under New Drug Application (NDA) 008-951, submitted by Smith Kline & French Laboratories. This made liothyronine sodium one of the first synthetic thyroid hormones to enter the U.S. market, arriving just seven years after the chemical synthesis of triiodothyronine was first described.

The approval came during an era when the FDA's drug evaluation process was far less rigorous than modern standards require. Pre-1962 drugs, approved before the Kefauver-Harris Amendment mandated proof of efficacy through adequate and well-controlled trials, were later reviewed under the Drug Efficacy Study Implementation (DESI) program conducted by the National Academy of Sciences 1. Cytomel survived this review. The DESI panel found sufficient evidence supporting its efficacy for its labeled indications, allowing it to remain on the market without interruption.

Smith Kline & French (later SmithKline Beecham, then GlaxoSmithKline) held the original NDA for decades. Pfizer eventually acquired the Cytomel brand. The drug's continuous market presence for nearly seven decades reflects both its clinical utility and the relative simplicity of its formulation as an oral tablet containing a single active thyroid hormone 2.

Approved Indications and Labeling

The current Cytomel label specifies three FDA-approved uses: hypothyroidism (as replacement or supplemental therapy), myxedema coma or precoma, and as a diagnostic agent in the T3 suppression test to differentiate suspected hyperthyroidism from thyroid gland autonomy.

For hypothyroidism, the label recommends starting doses of 25 mcg daily, with increases of up to 25 mcg every one to two weeks 3. Maintenance doses typically range from 25 to 75 mcg per day. The label explicitly states that liothyronine has a rapid onset of action (within hours) and a shorter half-life (approximately 2.5 days) compared to levothyroxine (T4), which has a half-life of 6 to 7 days. This pharmacokinetic profile produces more pronounced peak-to-trough fluctuations in serum T3 levels.

The myxedema coma indication is notable because the injectable formulation (Triostat) was not approved until 1999 under NDA 019201. Before that approval, clinicians had to administer oral Cytomel via nasogastric tube or rely on intravenous levothyroxine for this life-threatening emergency 4.

The Black Box Warning

Cytomel carries one of the most direct black box warnings in endocrinology. It reads: "Thyroid hormones, including CYTOMEL, should not be used for the treatment of obesity or for weight loss. In euthyroid patients, doses within the range of daily hormonal requirements are ineffective for weight loss."

The warning goes further. It states that larger doses may produce "serious or even life-threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects." This language dates to cases in the 1960s and 1970s when thyroid hormones were combined with amphetamines in weight-loss preparations, sometimes resulting in cardiac arrhythmias and death 5.

The FDA reinforced this warning in a 2004 label revision. Despite the warning, off-label use of liothyronine for weight management persists in some clinical settings, a practice that the American Thyroid Association (ATA) and the Endocrine Society have repeatedly advised against in euthyroid individuals 6.

Generic Entry and Bioequivalence Considerations

Generic liothyronine tablets entered the U.S. market through multiple Abbreviated New Drug Applications (ANDAs) beginning in the early 2000s. Current generic manufacturers include Mylan (Viatris), Sigmapharm, and Padagis. Generic versions are available in the same 5 mcg, 25 mcg, and 50 mcg tablet strengths as the branded product.

Thyroid hormone bioequivalence has been a contentious regulatory question. For levothyroxine, the FDA issued specific bioequivalence guidance in 2001 recognizing the narrow therapeutic index (NTI) of thyroid hormones. Liothyronine, with its shorter half-life and more variable serum levels, presents additional challenges. The FDA's current bioequivalence standards for liothyronine require 90% confidence intervals for AUC and Cmax to fall within 80% to 125% of the reference product 7.

The ATA published a statement in 2004 expressing concern about the substitution of branded thyroid hormone products with generics, noting that small differences in bioavailability can produce clinically significant changes in TSH levels 8. Some clinicians prefer to maintain patients on a single manufacturer's product rather than switching between generic formulations. This preference is not an FDA mandate but a clinical judgment based on the NTI classification.

The T3 Combination Therapy Debate

While not strictly a regulatory action, the scientific debate around T3 combination therapy has shaped how the FDA label is interpreted and prescribed. The 1999 trial by Bunevicius and colleagues published in the New England Journal of Medicine found that partial substitution of levothyroxine with liothyronine (replacing 50 mcg of T4 with 12.5 mcg of T3) improved cognitive performance, mood, and physical well-being in 33 patients over five weeks 9.

That study triggered over two decades of follow-up research. A 2006 meta-analysis by Grozinsky-Glasberg et al. analyzing 11 randomized controlled trials (N=1,216) concluded that T4/T3 combination therapy showed no consistent advantages over T4 monotherapy in body weight, serum lipids, quality of life, or depression scores 10. The 2014 ATA guidelines for hypothyroidism recommended against routine use of combination T4/T3 therapy, grading the evidence as "weak" and acknowledging that a subgroup of patients, possibly those with polymorphisms in the deiodinase type 2 gene (DIO2), might benefit 11.

The FDA label itself does not address combination therapy. It neither endorses nor prohibits the co-administration of liothyronine with levothyroxine. This regulatory silence has left clinical practice to be guided by society guidelines and physician judgment rather than FDA-mandated labeling.

Post-Market Safety Surveillance

The FDA Adverse Event Reporting System (FAERS) database contains reports associated with liothyronine spanning the full period of its market availability. The most commonly reported adverse events align with thyrotoxicosis symptoms: palpitations, tachycardia, tremor, heat intolerance, weight loss, and insomnia 12.

Cardiovascular risks dominate the serious adverse event profile. A 2020 retrospective cohort study using FDA Sentinel System data examined cardiovascular outcomes in patients prescribed liothyronine versus levothyroxine monotherapy 13. The study found a numerically higher rate of atrial fibrillation among liothyronine users, consistent with the known arrhythmogenic potential of supraphysiologic T3 levels. The association was most pronounced in patients over age 65 and those with pre-existing cardiac disease.

Bone mineral density loss represents another monitored safety signal. Exogenous thyroid hormone excess accelerates bone turnover. A meta-analysis published in the Annals of Internal Medicine found that TSH suppression from thyroid hormone therapy was associated with a 0.6% to 1.6% annual decrease in bone mineral density at the lumbar spine and femoral neck in postmenopausal women 14. This finding applies broadly to thyroid hormones and is not specific to liothyronine, but the rapid absorption and peak serum levels achieved with T3 may amplify acute bone resorption markers.

Label Revisions and Regulatory Milestones

The Cytomel label has undergone multiple revisions since the original 1956 approval. Key milestones include the following.

The 1984 revision added the black box warning language regarding weight loss, responding to accumulating case reports of harm from thyroid hormone misuse in diet preparations. The 2004 revision updated drug interaction sections to include anticoagulant potentiation and the effects of estrogen-containing oral contraceptives on thyroid-binding globulin levels 3.

The 2018 labeling update (Supplement 40) modernized the prescribing information format to the Physician Labeling Rule (PLR) structure, replacing the older format. This revision also expanded the warnings and precautions section to include adrenal insufficiency (noting the need to treat cortisol deficiency before initiating thyroid hormone replacement), effects on bone mineral density, and interactions with oral anticoagulants, insulin, and oral hypoglycemics 3.

No Risk Evaluation and Mitigation Strategy (REMS) has been required for liothyronine at any point in its regulatory history. The drug has never been subject to a formal FDA safety communication or Drug Safety Communication (DSC), reflecting its well-characterized safety profile within labeled indications and doses.

Compounded Liothyronine: A Regulatory Gray Area

Compounded liothyronine preparations, including sustained-release T3 capsules, represent a distinct regulatory category. The FDA does not approve compounded drugs. They are prepared by compounding pharmacies under Section 503A or 503B of the Federal Food, Drug, and Cosmetic Act 15.

Sustained-release T3 formulations are frequently prescribed by integrative and functional medicine practitioners who argue that the immediate-release commercial product produces undesirable serum T3 spikes. No FDA-approved sustained-release liothyronine product exists. The ATA's 2014 hypothyroidism guidelines noted the lack of evidence supporting compounded thyroid preparations and expressed concern about potency variability 11.

The FDA has issued warning letters to compounding pharmacies producing thyroid hormone preparations that were found to have inconsistent potency. A 2018 analysis of compounded T3 capsules found that 30% of tested samples fell outside the USP potency range of 90% to 110% of the labeled dose 16. This variability is a direct patient safety concern, given the narrow therapeutic index of thyroid hormones.

International Regulatory Status

Outside the United States, liothyronine carries different regulatory designations. The European Medicines Agency (EMA) does not have a centralized marketing authorization for liothyronine; instead, individual member states regulate it through national procedures. In the United Kingdom, liothyronine availability became a significant public health issue when the price of generic liothyronine rose from approximately £4.46 per pack in 2007 to over £258 per pack by 2017, leading to restricted prescribing by the NHS and an investigation by the Competition and Markets Authority 17.

Australia's Therapeutic Goods Administration (TGA) lists liothyronine on the Australian Register of Therapeutic Goods, though access has been limited, with many patients relying on Special Access Scheme provisions. Health Canada authorizes liothyronine under a Drug Identification Number (DIN), with the product available in 25 mcg tablets.

Current Prescribing Patterns and Regulatory Outlook

According to IQVIA data, liothyronine prescriptions in the United States totaled approximately 1.4 million in 2023, representing a small fraction of the estimated 80 million annual thyroid hormone prescriptions dominated by levothyroxine 18. Use is concentrated among endocrinologists and a subset of primary care physicians who manage patients reporting persistent symptoms on T4 monotherapy.

The FDA has not signaled any planned regulatory changes for liothyronine. No Citizen Petitions requesting label modifications are currently pending. The 2020 ATA/AACE joint statement reaffirmed that levothyroxine monotherapy remains the standard of care for hypothyroidism, while acknowledging that T3-containing therapy might be considered on a trial basis for patients with persistent symptoms despite biochemical euthyroidism on T4 alone, provided that TSH is monitored closely and kept within the reference range 11.

Clinicians prescribing Cytomel or generic liothyronine should monitor TSH every 6 to 8 weeks after dose changes and target a TSH within the age-appropriate reference range, typically 0.4 to 4.0 mIU/L for adults under 70 years.